Eone Dianamics Genome Center (EDGC) said Tuesday it would provide two liquid biopsy services detecting cancer and monitor prognosis to Europe, after a year-long study with Pb Medicom-In, a Ukrainian precise medicine clinic. 

EDGC also supplies blood collecting tubes to the Pb Medicom-In. 

It has established an online platform, based on which foreign hospitals send blood samples to Korea, EDGC headquarters conduct experiments and analysis, and foreign medical workers confirm results, the company said. 

“We are conducting research and development on early cancer diagnosis and track monitoring targeting all cancers, based on cell-free DNA (cfDNA), inside blood using the liquid biopsy technology,” an EDGC official said. “For early diagnosis of cancer, 0.01 percent, or one in 10,000 of cfDNA needs to be detected. EDGC has secured such technology, developed together with Grail, the U.S. liquid biopsy tech developer.” 

Cho Sung-min, director of the Healthcare Business Department at EDGC, said, “Liquid biopsy has been recognized as high value-added innovation technology in Asia. UMH, the biggest medical group in Hong Kong, has supplied such service since 2019.”

EDGC will step up efforts to enter Russia and 10 other Commonwealth Independent States countries, he added.